Corner Therapeutics is a US developer of immune therapies and vaccines focused on creating vaccines that confer lifelong protection from cancer and infectious diseases. The company uses an antigen-agnostic technology intended to enable the immune system to engineer long-living, disease-fighting T cells. Corner is applying this approach to both oncology and infectious-disease targets, with specific efforts toward HIV, influenza and COVID-19. Grant funding from the Bill & Melinda Gates Foundation is supporting the company’s infectious-disease work. Corner raised $54 million in a Series A to advance its vaccine programs and technology.

Total raised

$54M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024